Amid rapid scientific progress, familiar targets continue to capture momentum while promising alternatives struggle for visibility. A quiet cognitive bias shapes how opportunities are assessed and prioritized. For companies developing novel science, recognizing this pattern—and designing strategies that anticipate and counter it—will be essential to advancing differentiated programs in a landscape defined by precedent.

Federal grant volatility is disrupting early-stage biotech, with programs like CDMRP facing steep cuts and new NIH restrictions limiting access. As delays and cancellations increase, traditional budgeting falls short. This piece explores how scenario-based FP&A helps companies navigate uncertainty, prioritize pipelines, and sustain innovation in a shifting funding landscape.

Organs-on-chips are at the forefront of preclinical innovation, promising to usher in a new era of patient-centric drug development.

Explore new targets for CRISPR-based therapeutics, as well as challenges associated with commercialization of these therapies.

After a brutal two-year downturn, biotech is showing real signs of life in 2024. A strong start to IPO activity, the XBI's 38% Q4 surge, and a resurgent M&A market, backed by over $500 billion in pharma firepower, are fueling renewed investor optimism. This post breaks down the forces driving the recovery, from anticipated interest rate cuts to pending patent cliffs, and explains why investors, chastened by 2022's downturn, are approaching this cycle with sharper discipline a